MetaCap

Taysha Gene Therapies Statistics

NASDAQ: TSHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

3.72-0.05 (-1.33%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Taysha Gene Therapies by the numbers

Taysha Gene Therapies has a market capitalization of $1.21 billion based on 326.05M shares outstanding. With trailing EPS of $-0.42, Taysha Gene Therapies is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 14.5% below its 50-day average and 29.6% below its 200-day average.

Average daily trading volume is 3.59M shares, or about $13.4 million in dollar volume.

Summary generated from market data by MetaCap's automated system. Methodology

TSHA valuation vs. peer median

TSHA compared with the median of 8 peer companies
MetricTSHAPeer medianDifference
Market cap$1.21B$1.39B-13%
Avg. volume3.59M698.28K+414%

Peer median across 8 companies: NVAX, VOR, IMCR, MESO, INBX, WWB, ALVO, RXRX.

Valuation

Price / sales (latest FY)
124.11
EPS (TTM)
$-0.42

Price and trading

Previous close
3.77
Open
3.67
Day range
3.60 – 3.80
52-week range
3.46 – 7.30
52-week change
-11.22%
Beta
—
Volume
3.15M

Dividends and events

Annual dividend
None
Next earnings date
Nov 12, 2026

Additional statistics

Market Cap
1.21B
Forward Pe
-9.60
Eps
-0.42
Dividend Yield
0.00%
Dividend Rate
0.00
Week52 High
7.30
Week52 Low
3.46
Avg Volume
3.59M
Shares Outstanding
326.05M
Ma50
4.35
Ma200
5.28
Earnings Date
Nov 12, 2026
Pct From52w High
-49.04%
Pct From52w Low
7.67%

Related